Results 51 to 60 of about 333,288 (246)

Developmentally Guided Differentiation of Ventral Midbrain Dopaminergic Cells Validated in Proteopathy‐Based Parkinson's Disease Models

Advanced Science, EarlyView.
A developmentally guided protocol reproducibly specifies EN1‐positive ventral midbrain dopaminergic (vmDA) progenitors from human pluripotent stem cells and yields functional vmDA neurons. Optogenetic induction of α‐synuclein aggregation elicits selective degeneration of TH‐positive neurons in 2D cultures and 3D neurospheroids, while transplanted ...
Heechang Moon, Heejeong Kim, Elliot H. Lee, Hanseul Kim, Ji Hun Kim, Huisu Jeong, Jiwon Cheon, Ga Ram Jeong, Byoung Dae Lee, Jae‐Won Cho, Soo‐Jin Oh, Yunjong Lee, Yohan Oh   +12 more
wiley   +1 more source

EphB1 Receptor Blockade Augments Morphine Antinociception via Inhibiting GRK2‐Mediated µ‐Opioid Receptor Internalization

Advanced Science, EarlyView.
Administration of opioids activates ephrinB2‐EphB1 receptor signaling. Activated EphB1 receptors induce GRK2‐mediated phosphorylation of MOR at Ser375, which initiates the internalization of MOR and reduces opioid antinociception at the behavioral level. ABSTRACT Opioids are the primary treatment for severe pain in clinical practice.
Bo Peng, Xiaqing Lin, Hongyu Yao, Cheng Li, Huabao Liao, Yuexin Liu, Boxu Cao, Xue‑Jun Song   +7 more
wiley   +1 more source

Bacteria‐Derived 1‐Allylpiperazine Alleviates Symptoms of Parkinson's Disease Model by Promoting Autophagy

Advanced Science, EarlyView.
Parkinson's disease currently has no disease‐modifying therapies. In Caenorhabditis elegans, Escherichia coli E8 alleviates α‐synuclein‐provoked PD‐related defects through its bioactive metabolite 1‐ALPP, which combats PD by triggering AMPK/mTOR/HLH‐30‐dependent autophagy and suppressing α‐synuclein LLPS‐mediated fibrillization.
Mingqin Qu, Xinyuan Zhang, Xinyi Chen, Jiaxin Shi, Meng Xu, Fuhao Wang, Jinling Lv, Jiaman Sun, Weiyi Niu, Zihan Liu, Li Li, Fufeng Liu, Xiangming Wang   +12 more
wiley   +1 more source

Dopamine agonist switching in Parkinson\u27s disease

There are a number of situations for patients with Parkinson\u27s disease in which a safe and efficacious switch from treatment with one dopamine agonist to another may be required.
Heywood P, Grosset D, Chaudhuri KR, MacMahon D, Needleman F, Burn D, Morgan E, Macphee G, Stewart D   +8 more
core   +4 more sources

A Fluorogenic Cysteine‐Tetrapeptide Tagging Strategy for Nonperturbative Protein Labeling and Protein–Ligand Interaction Tracking

Advanced Science, EarlyView.
A compact Phe‐Cys‐Pro‐Phe (FCPF) tag and an environment‐sensitive SBD‐Cl‐derived probe form a sequence‐selective fluorogenic pair for wash‐free live‐cell protein imaging. This minimally perturbing chemistry allows flexible insertion at termini or loops, produces strong fluorescence upon local microenvironment confinement, supports FRET‐assisted ...
Xiao Wang, Xingcan Pan, Yongling Ying, Ziqian Bai, Jingming Zhang, Zhuang Shao, Jialiang Qian, Hongwei Li, Ning Zhang, Fan Yang, Yuan Liu, Xing Yang   +11 more
wiley   +1 more source

Receptores de dopamina y heterómeros de receptores de dopamina en la modulación de la neurotransmisión [PDF]

, 2012
[spa] La mayoría de los ligandos de GPCR que actúan como agonistas, antagonistas o agonistas inversos, se unen al mismo dominio del receptor reconocido por los agonistas endógenos, es decir, el lugar de unión ortostérico.
González González, Sergio
core   +4 more sources

Central dopamine D2 receptors regulate plasma glucose levels in mice through autonomic nerves

Scientific Reports, 2020
Recent evidence suggests that the central nervous system (CNS) regulates plasma glucose levels, but the underlying mechanism is unclear. The present study investigated the role of dopaminergic function in the CNS in regulation of plasma glucose levels in
Hiroko Ikeda, Naomi Yonemochi, Risa Mikami, Manabu Abe, Meiko Kawamura, Rie Natsume, Kenji Sakimura, John L. Waddington, Junzo Kamei   +8 more
doaj   +1 more source

Dopamine agonist and tamoxifen combination therapy for a prolactin-secreting pituitary tumor resistant to dopamine agonist monotherapy: Case report and review

Interdisciplinary Neurosurgery, 2020
Background: The majority of prolactin-secreting pituitary macroadenomas are effectively managed with dopamine-agonist therapy alone. Although surgical resection and radiotherapy are second- and third-line treatment options, there remains a paucity of ...
Zachary K. Christian, Kimmo J. Hatanpaa, Richard J. Auchus, Stephen R. Hammes, Ankur R. Patel, Bruce E. Mickey   +5 more
doaj   +1 more source

Synergistic activation of dopamine D1 and TrkB receptors mediate gain control of synaptic plasticity in the basolateral amygdala. [PDF]

PLoS ONE, 2011
Fear memory formation is thought to require dopamine, brain-derived neurotrophic factor (BDNF) and zinc release in the basolateral amygdala (BLA), as well as the induction of long term potentiation (LTP) in BLA principal neurons.
Chenchen Li, Joanna Dabrowska, Rimi Hazra, Donald G Rainnie   +3 more
doaj   +1 more source

Cross‐Organ Multi‐Omics Profiling of Systemic Alterations in 5xFAD Mice and Changes Associated with Huanglian Jiedu Decoction Treatment

Advanced Science, EarlyView.
Cross‐organ multi‐omics reveals coordinated inflammatory and metabolic disturbances in 5xFAD mice. Huanglian Jiedu Decoction improves cognition and alleviates brain and liver abnormalities. Complementary hepatocyte–microglia conditioned‐medium experiments suggest PPAR‐γ involvement in treatment‐associated changes in microglial inflammation, providing ...
Wenya Gao, Jing Gao, Xiaohui Su, Xiangying Kong, Xiaolu Wei, Tunan Ding, Tiantian Guo, Shuangrong Gao, Yanyan Zhou, Junyi Zhou, Haiyu Zhao   +10 more
wiley   +1 more source